A randomized phase III study of single-agent amrubicin Vs. Carboplatin/Etoposide in elderly patients with extensive-disease small-cell lung cancer

Clinical Lung Cancer

Volumn 15, Issue 2, 2014, Pages 96-102

  Sekine, Ikuo ^a   Okamoto, Hiroaki ^b   Horai, Takeshi ^c   Nakagawa, Kazuhiko ^d   Ohmatsu, Hironobu ^e   Yokoyama, Akira ^f   Katakami, Nobuyuki ^g   Shibuya, Masahiko ^h   Saijo, Nagahiro ^e   Fukuoka, Masahiro ^d  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f NIIGATA CANCER CENTER HOSPITAL   (Japan)

^g INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^h TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Chemotherapy; Interstitial lung disease; Pulmonary disease; Pulmonary toxicity; Treatment related death

Indexed keywords

AMRUBICIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE;

AGED; BRAIN NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG NEOPLASMS; MALE; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SECONDARY; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; QUALITY OF LIFE; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 84894033487     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.11.006     Document Type: Article

References (20)

1. Y. Toyoda, T. Nakayama, and A. Ioka et al. Trends in lung cancer incidence by histological type in Osaka, Japan. Jpn J Clin Oncol 38 2008 534 539
2. J.P. van Meerbeeck, D.A. Fennell, and D.K. De Ruysscher Small-cell lung cancer Lancet 378 2011 1741 1755
3. A.G. Pallis, F.A. Shepherd, and D. Lacombe et al. Treatment of small-cell lung cancer in elderly patients Cancer 116 2010 1192 1200
4. H. Okamoto, K. Watanabe, and H. Kunikane et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 Br J Cancer 97 2007 162 169
5. M. Yamamoto, A. Takakura, and N. Masuda Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin Drug Des Devel Ther 2 2008 189 192
6. T. Sugiura, Y. Ariyoshi, and S. Negoro et al. Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer Invest New Drugs 23 2005 331 337
7. T. Yana, S. Negoro, and M. Takada et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study Invest New Drugs 25 2007 253 258
8. S. Onoda, N. Masuda, and T. Seto et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301 J Clin Oncol 24 2006 5448 5453
9. A. Inoue, S. Sugawara, and K. Yamazaki et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402 J Clin Oncol 26 2008 5401 5406
10. R. Jotte, P. Conkling, and C. Reynolds et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy J Clin Oncol 29 2011 287 293
11. D.S. Ettinger, R. Jotte, and P. Lorigan et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer J Clin Oncol 28 2010 2598 2603
12. E. Saitoh, Y. Yokomizo, and C.H. Chang et al. Cross-cultural validation of the Japanese version of the lung cancer subscale on the functional assessment of cancer therapy-lung J Nihon Med School (Nihon Ika Daigaku zasshi) 74 2007 402 408
13. C. Hamashima, and K. Yoshida A study of the reliability of health state valuations in the Japanese EuroQol instrument Environ Health Prev Med 6 2001 189 191
14. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
15. M. Nakao, T. Oguri, and T. Suzuki et al. Amrubicin monotherapy for elderly patients with previously treated lung cancer Intern Med 49 2010 1857 1862
16. S. Igawa, S. Ryuge, and T. Fukui et al. Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer Int J Clin Oncol 15 2010 447 452
17. K. Yoh, H. Kenmotsu, and Y. Yamaguchi et al. Severe interstitial lung disease associated with amrubicin treatment J Thorac Oncol 5 2010 1435 1438
18. S. Kudoh, H. Kato, and Y. Nishiwaki et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study Am J Respir Crit Care Med 177 2008 1348 1357
19. H. Kenmotsu, T. Naito, and M. Kimura et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer J Thorac Oncol 6 2011 1242 1246
20. S.S. Ramalingam, S.E. Dahlberg, and C.J. Langer et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599 J Clin Oncol 26 2008 60 65